Responses

PDF
Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Randomised control trial of topical ciclosporin A in steroid

    Dear editors

    We read with interest the article 'Randomised controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis' (Br J Ophthalmol. 2006 Apr;90(4):461-4.) This article evaluated the use of cyclosporine A in treating steroid dependent severe allergic conjunctivitis, and has the merit of a randomized study design, comparing 0.05% cyclosporine versus placebo. The sample size of the...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Topical use of cyclosporine A

    Dear Editor,

    I have just finished reading the interesting paper by Daniell et al and, being one of the first authors (Secchi AG et al, AJO, 1990, 110, 137- 42) to become interested in the topical use of Cyclosporine A in "allergic" conditions concerning the ocular surface, I would like to make a few comments - based above all on a 20-year experience in the treatment of vernal keratoconjunctivitis (VKC) with topi...

    Show More
    Conflict of Interest:
    None declared.